This study aimed to assess the accuracy and outcomes of coronary computed tomography angiography (CCTA) performed in a regional hospital in Singapore.
INTRODUCTION
Coronary artery disease (CAD) is one of the leading causes of mortality and morbidity in Singapore. Catheter coronary angiography (CCA) is considered the gold standard for diagnosing CAD, as it is highly reliable and has the ability to determine the extent, location and severity of coronary obstructive lesions. (1) (2) (3) (4) (5) (6) (7) (8) However, CCA is not suitable for all patients with suspected CAD due to its invasive nature and risk of complications. Furthermore, not all conventional angiography procedures proceed to intervention. Weighing the risks of CCA for a patient who may not require intervention may tip the scales in favour of a noninvasive test for diagnosing coronary stenosis. (9, 10) The continuous advances in coronary computed tomography angiography (CCTA) technology have also improved the diagnostic performance of noninvasive coronary imaging, and the high negative predictive values (NPVs) afforded by CCTA enable reliable exclusion of significant coronary stenosis. (11, 12) Other additional advantages of CCTA include its ability to provide prognostic information and guide management in patients with suspected CAD. (13) (14) (15) (16) An accurate, noninvasive alternative evaluation method for diagnosing CAD is highly desirable, particularly in patients with a low-to-intermediate pre-test likelihood of CAD, in whom CAD cannot be diagnosed or excluded based on clinical assessment alone. (10, 17, 18) 
METHODS
The CCTA database at Changi General Hospital (CGH), Singapore, was analysed over a 24-month period from January 2013 to December 2014. Electronic medical records, CCA and CCTA images and reports from the cardiology and radiology Picture Archival and Communication databases were analysed to determine major adverse cardiovascular events (MACE) and CCA results in the patient subsets described in detail below.
CCTA findings were deemed positive if coronary artery stenosis ≥ 50% was reported or if it was graded as 'moderate' or 'severe', and negative if there was < 50% stenosis in all coronary arteries. CCA findings were deemed positive if coronary artery stenosis ≥ 50% was reported. The definition of MACE included the following events: death, acute myocardial infarction, unstable angina, acute coronary syndrome and cardiac revascularisation. Information on MACE was determined from our hospital's electronic medical records.
The database query returned 728 patients who had CCTA performed for the assessment of suspected CAD during the study period. The study population consisted of low-to-intermediate risk patients with an age range of 15-87 years who presented with the chief complaint of acute-onset chest pain and were referred for CCTA by cardiologists, emergency department physicians and other clinicians, at the referring clinician's discretion. A total of 35 patients Accuracy and clinical outcomes of coronary CT angiography for patients with suspected coronary artery disease: a single-centre study in Singapore with prior coronary artery bypass graft (CABG) surgeries, anomalous arteries or other vascular anomalies, and those with CCA before CCTA was performed, were excluded from analysis. Another nine patients were excluded due to incomplete CCTA data, four due to non-interpretable images and one was lost to follow-up (Fig. 1 ).
Patients were analysed in two groups: one group for accuracy analysis and the other for prognostic analysis. Of the 679 patients, 101 (14.9%) had undergone both CCTA and CCA and were identified for accuracy analysis. 677 patients were evaluated for MACE and used for prognostic analysis. All patients analysed had undergone retrospective or prospective electrocardiography (ECG)-gated CCTA using a 320-row detector scanner (Toshiba Aquilion ONE, Toshiba Medical Systems Corporation, Tochigi, Japan). Patient preparation involved a four-hour fast and insertion of an 18 G cannula in the right antecubital vein. A beta-blocker (metoprolol tartrate; Betaloc, AstraZeneca, Cambridge, UK) was administered intravenously for patients without contraindications and with heart rates > 60 beats/minute, and 0.5 mg sublingual glyceryl trinitrate was given before the start of the scan. Patients were positioned feet first with arms above their head and asked to perform breath-hold exercises in the scanner to ensure that their heart rate did not fluctuate more than 10% during the breath hold.
Initial anteroposterior scout computed tomography was performed, centred at the sternal notch with coverage from the supraclavicular region to lung bases. Scan coverage from the pulmonary trunk to the apex of the heart included the entire heart with a 2-3 cm allowance for anatomical excursion during breath hold. 60 mL iodinated contrast and 40 mL saline bolus chaser was injected intravenously via a dual-pump injector at a rate of 4.5 mL/second as part of the acquisition protocol. A bolus-tracking method was used to trigger the scan acquisition (monitoring level: carina; monitoring delay: five seconds; placement of region of interest: descending aorta, Hounsfield unit threshold: 180). ECG dose modulation was used for radiation dose reduction. The scan acquisition was done using the parameters in Table I .
Categorical data was presented as frequency (percentage). Continuous data was presented as mean ± standard deviation for parametric distribution and median (interquartile range) for non-parametric distribution. In prognostic analysis, the association between CCTA and MACE was assessed by chi-square test. A twotailed p-value < 0.05 was considered statistically significant. In accuracy analysis, the accuracy, sensitivity, positive predictive value (PPV), specificity and NPV of CCTA were evaluated for correct identification of the outcome of CCA. A measure of at least 70% was considered as clinically acceptable. Prevalence of CCA was also reported. Statistical data analysis was performed with IBM SPSS Statistics version 19.0 (IBM Corp, Armonk, NY, USA).
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Accuracy analysis
101 patients (578 did not have CCA)
Prognostic analysis
677 patients (2 lost to follow-up for MACE) Fig. 1 Flowchart shows the inclusion criteria for the study. CABG: coronary artery bypass graft; CCA: catheter coronary angiography; CCTA: coronary computed tomography angiography; MACE: major adverse cardiovascular events; PCI: percutaneous coronary intervention In the per-vessel analysis group, CCTA was compared with CCA for the left main artery, left anterior descending artery (LAD), left circumflex artery (LCX) and right coronary artery (RCA) individually. There were 15 false-negative vessels -two in the LAD, five in the RCA and eight in the LCX. Further evaluation of CCTA images revealed that in the false-negative group, one LAD, three RCA and one LCX lesions were obscured by heavily calcified plaques and reported as < 50% stenosed. Two LCX positive lesions were missed due to vein crossover and another due to the poor quality of the images obscuring the LCX origin where the lesion was located. One RCA lesion was missed due to poor image quality and another RCA lesion was missed due to diffuse plaque that made it difficult to appreciate the amount of narrowing. Among the false positives, seven out of 13 studies had been performed on patients who had high calcium scores in the range of 499-4,650 units using the Agatston scoring method, which is known to have an adverse effect on luminal assessment during CCTA due to a phenomenon known as 'blooming' artefact (Fig. 2) .
The mean age of the study sample was 53 ± 13 (range 15-87) years and 255 (37.6%) patients were female. The mean duration of patient follow-up was 360 (range 120-840) days. Of 513 negative CCTA patients, none went on to develop MACE during the follow-up period, and of the 164 positive CCTA patients, 19 (11.6%) developed MACE (p < 0.001). Among the patients who developed MACE, three patients were admitted with unstable angina or acute coronary syndrome and a total of 15 (9.1%) revascularisation procedures were subsequently performed. The angiograms of a patient with positive CCTA who developed MACE are shown in Fig. 3 . The 55-year-old Chinese man presented with chest pain without ECG changes or a rising trend of cardiac enzymes. He underwent conventional CCA that confirmed the presence of severe stenosis in the mid LAD, which was revascularised by balloon angioplasty.
DISCUSSION
The main objective of the study was to assess whether the accuracy of CGH's CCTA service is comparable with previously published single-centre trial data, and if CCTA is a useful tool for excluding patients who go on to develop MACE. The study was designed to mirror the real-world situation, especially in the context of a busy clinical service and emergency department that relies on CCTA to triage patients for discharge or admission, and as a decision-making tool for assessing the need for further investigation with CCA. (17, (19) (20) (21) A comparison showed that our results are commensurate with the available literature (Table II) , with a good NPV of 85.7% and a very high sensitivity of 99.0%. The overall accuracy of CCTA compared to CCA was 86.1%.
The present study also sought to determine whether a negative CCTA prognostically conferred a low risk for MACE during follow-up, and this was found to be true: CCTA had an excellent NPV of 100% for cases that went on to develop MACE within 12 months. This implied a calculated average one-year MACE-free warranty period for negative CCTA. The 0% rate of MACE at a mean of 12 months' follow-up is comparable with the published data for negative myocardial perfusion scans and stress echocardiography. Metz et al (18) found that the annual event rates for a negative myocardial perfusion scan and stress echocardiogram were 0.45% and 0.54% per year, respectively. Studies by Genders et al (21) and Min et al (22) have suggested that CCTA is an excellent cost-effective triage test prior to CCA in patients with low-to-intermediate pre-test probability of CAD. Suh et al (23) also demonstrated the usefulness of CCTA for selecting CABG surgery candidates in patients suspected of CAD. In addition, it is an excellent tool for assessment of both grafts 
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and native coronary arteries in patients after CABG surgery. (24) Future improvements may occur, as efforts are being made to reduce the radiation dose involved in CCTA while maintaining the required diagnostic accuracy.
(25-27) Table III shows a comparison of MACE prognostic accuracy rates in this study with those in the available published literature. The PPV of CCTA for MACE of 11.6% was extremely low, which could be due to several factors, such as aggressive medical therapy before patients developed MACE and the nature of the retrospective study versus longitudinal prospective data collection, and is reflective of the local referral pattern in which many patients with positive tests for coronary ischaemia are referred to a tertiary cardiac centre for further specialist management, including CCA.
This study had several limitations. First, prognostic information was collated retrospectively in a review of patient records rather than as a prospective, observational trial. However, the longer follow-up time in the medium term could help to compensate for this limitation. Second, not all positive CCTA patients went on to have catheter correlation, as CCA was performed only after cardiology review and was based on an assessment of the patient's clinical symptoms and other tests, including functional imaging. The study was performed with a real-world model in mind, based on an intention-todiagnose rather than an intention-to-treat model. Hence, we did not exclude cases with high coronary calcium scores (even those > 600 units) and no studies were excluded unless the images were deemed non-diagnostic or non-interpretable. A study by Park et al (28) suggested that although CCTA has limited value due to its low diagnostic accuracy in imaging heavily calcified plaques, it can provide information about mixed and non-calcified plaques that result in significant stenosis, and therefore helps in assessing the severity of CAD in patients with high calcium scores. Third, the accuracy subgroup analysis had a small sample size, as not all cases with positive CCTA went on to have CCA. Furthermore, clinical reports for CCA rather than blinded CCA were used, which is in keeping with the normal clinical management and decision-making process of our institution. Fourth, data analysis of follow-up for MACE was limited to one institutional cluster only due to limitations in electronic health record coverage at the time of the study. If the patient did not have MACE in the same institutional cluster, it would not be identified. Hence, our results may appear to be better than in reality.
In conclusion, diagnostic CCTA at our institution had an accuracy that is in line with published trial data, as well as excellent sensitivity and NPV. The 0% event rate of MACE at a mean of one year of follow-up after negative CCTA highlights the excellent prognosis and ability to avoid further unnecessary testing. This confirms the role of CCTA as a robust, first-line, noninvasive diagnostic test for detecting CAD and providing essential information to guide management, therapy and prognostic evaluation in patients with suspected CAD. It is particularly valuable in patients with a low-to-intermediate pre-test likelihood of CAD, in whom the condition cannot be diagnosed or excluded based on clinical assessment alone.
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